Bringing together clinical and experimental scientists involved in the study of myeloma.

Thank you!

Outcomes for patients with multiple myeloma have improved with approval of several therapies. Despite this MM, remains incurable. Recent results have also highlighted the heterogeneity in outcomes in patients with multiple myeloma. Improved understanding of the clinical and disease specific prognostic factors and the availability of multiple classes of therapies has necessitated discussions on patient populations for evaluation in clinical trials of novel therapies. Additionally, as new therapies are moved into earlier lines, it is important to evaluate the appropriateness of the control arms for clinical trials.

This workshop is intended to discuss disease setting considerations in MM, with a focus on defining patient populations for enrollment onto clinical trials for MM. This meeting will bring together representatives from the physician community, patients, pharmaceutical industry and regulatory scientists.

Goals and Objectives
– Discuss eligibility criteria for MM clinical trials in different disease settings
– Discuss considerations in defining patient populations
– Review common goals and methods for clinical trial conduct

IMS is pleased to announce that the 5th Annual Immune Effector Cell Therapies in Multiple Myeloma Workshop will take place from March 23-24, 2024 in Boston, MA.

Tentative Agenda

Are you a hematologist or oncologist treating patients with multiple myeloma?
If so, this 90-minute webinar is for you!

This high-impact, 90-minute educational program seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engages, and CAR T therapies among healthcare professionals.

Are you a hematologist or oncologist treating patients with multiple myeloma?
If so, this 90-minute webinar is for you!

This high-impact, 90-minute educational program seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engages, and CAR T therapies among healthcare professionals.

Join us for a dynamic educational workshop on the diagnosis, treatment, and monitoring of plasma cell malignancies, including current practices and opportunities for improvement. This workshop will include lectures plus roundtable discussions around hot and controversial topics, featuring point-counterpoint conversations between invited speakers and local hematologists based on both challenging questions and clinical cases.

Preliminary Agenda

Mark your calendars for the 21st IMS Annual Meeting in Rio de Janeiro, Brazil!

The 21st IMS Annual Meeting will take place in Rio de Janeiro, Brazil from September 25-28, 2024.

More details will be available soon.